Boston musings.
P2B or P3 may be the burning question.
Pathways??
I wonder if the new HIV/225 patents will be part of a change of tack, with regard to the parameters of the next trial. Will they pursue eradication or will they pursue to prove the human value of the immune response over a longer period.
Is a treatment interruption trial, as mentioned previously by MM in an interview, no longer a pipedream here?
Will they take aim at both?
How?
The Boston CROI connection, page-18
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.001(1.89%) |
Mkt cap ! $48.72M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $6.98K | 133.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 151165 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 86242 | 1 |
View Market Depth
| Last trade - 15.32pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.3¢ | 5.2¢ | 38302 | ||
| Last updated 11.25am 24/05/2024 ? | |||||
| BIT (ASX) Chart |